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ABSTRACT High levels of the plasminogen activa-
tors, but also their inhibitor, plasminogen activator
inhibitor 1 (PAI-1), have been documented in neovas-
cularization of severe ocular pathologies such as dia-
betic retinopathy or age-related macular degeneration
(AMD). AMD is the primary cause of irreversible pho-
toreceptors loss, and current therapies are limited.
PAI-1 has recently been shown to be essential for
tumoral angiogenesis. We report here that deficient
PAI-1 expression in mice prevented the development of
subretinal choroidal angiogenesis induced by laser pho-
tocoagulation. When systemic and local PAI-1 expres-
sion was achieved by intravenous injection of a replica-
tion-defective adenoviral vector expressing human
PAI-1 cDNA, the wild-type pattern of choroidal angio-
genesis was restored. These observations demonstrate
the proangiogenic activity of PAI-1 not only in tumoral
models, but also in choroidal experimental neovascu-
larization sharing similarities with human AMD. They
identify therefore PAI-1 as a potential target for thera-
peutic ocular anti-angiogenic strategies.—Lambert, V.,
Munaut, C., Noe¨l, A., Frankenne, F., Bajou, K., Gerard,
R., Carmeliet, P., Defresne, M. P., Foidart, J.-M., Rakic,
J.-M. Influence of plasminogen activator inhibitor type
1 on choroidal neovascularization. FASEB J. 15,
1021–1027 (2001)
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Choroidal neovascularization growing under the
retina in severe forms of age-related macular degener-
ation (AMD) causes irreversible photoreceptors loss
and the primary source of blindness in the Western
world. Insight into the molecular mechanisms associ-
ated with subretinal neovascularization is important
since current therapeutic modalities are limited and
concern only a small percentage of affected individuals.
Molecular signals involved in the development of
choroidal neovascularization are not well defined.
Alpha-v integrins show a specific expression pattern
during retinal angiogenesis (1) and antibodies to this
integrin or its ligands such as vitronectin inhibit neo-
vascularization in different retinal models (2–4).
Among growth factors, several lines of evidence suggest
that vascular endothelial growth factor (VEGF) could
be implicated in the pathogenesis of AMD since this
cytokine is present in pathological specimens (5, 6) and
is expressed in several models of hypoxia-related retinal
neovascularization (7). However, VEGF retinal overex-
pression alone was not able to induce choroidal neo-
vascularization in a transgenic mouse model (8), sug-
gesting either a retinal specificity in the mechanisms
controlling angiogenesis or a requirement for addi-
tional angiogenic molecules in AMD. In the intact
choroid, polarized secretion of VEGF by retinal pig-
ment epithelium could play an important role in the
maintenance of a normal choriocapillaris (9). Recent
studies suggest also a role for Fas ligand in the control
of choroidal neovascularization (10).
Angiogenesis is an invasive process that requires
proteolysis of the extracellular matrix, proliferation,
and migration of endothelial cells with simultaneous
synthesis of new matrix components. Such migratory
and tissue remodeling events are regulated by different
proteolytic systems including matrix metalloproteases
(MMPs) and serine proteases of the plasminogen/
plasminogen activator system. The specific roles of
MMPs, plasminogen activators, and their inhibitors in
neovascular chorioretinopathies remain largely unex-
plored. In retinal pathology, a mutation in a tissue
inhibitor of MMPs (TIMP3) is associated with a rare
form of macular dystrophy (11), and the expression of
several MMPs has been demonstrated in human cho-
roidal neovascular membranes (12). Urokinase-type
(uPA) and tissue-type (tPA) plasminogen activators are
serine proteases, both able to activate the zymogen
plasminogen into plasmin. Plasmin is a broadly acting
enzyme that degrades extracellular matrix proteins and
activates pro-MMPs and growth factors (13). Plasmino-
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gen activator inhibitor type-1 (PAI-1) is the main phys-
iological inhibitor of uPA and tPA. It not only regulates
the proteolytic activity of uPA, but also determines the
level of uPA bound to its cell surface receptor (uPAR)
by promoting the rapid endocytosis of the trimolecular
uPA-PAI-1–uPAR complex (14). The importance of
PAI-1 for tumoral angiogenesis has recently been dem-
onstrated in vivo in experimental squamous cell carci-
nomas (15). Elevated PAI-1 levels have been correlated
clinically not only with a poor prognosis in patients
suffering from a variety of cancers (16), but also with
various chorioretinal pathologies (17, 18).
To evaluate the biological relevance of PAI-1 in
subretinal angiogenesis, we induced choroidal neovas-
cularization in vivo with argon laser burns (19) into
PAI-12/2 and wild-type (WT) mice. A choroidal neo-
vascular membrane with leakage on fluorescein angio-
grams was produced at laser impacts in WT mice but
not in PAI-1-deficient mice. In these PAI-12/2 mice,
choroidal neovascularization similar to that occurring
in WT mice was restored when PAI-1 expression was
achieved by injecting a recombinant adenoviral vector
bearing PAI-1 cDNA. These observations highlight the
proangiogenic activity of PAI-1 in choroidal neoangio-




Animal experiments were performed in compliance with the
Association for Research in Vision and Ophthalmology state-
ment for the Use of Animals in Ophthalmic and Vision
Research. Homozygous PAI-1-deficient mice (PAI-12/2) and
the corresponding WT mice (PAI1/1) of either sex, with a
mixed genetic background of 87% C57BL/6 and 13% 129
strain, were used throughout this study (20). There were five
or more mice in each group. The animals were maintained
with a 12 h light/12 h dark cycle and had free access to food
and water.
Laser photocoagulation and fluorescein angiograms
Choroidal neovascularization was induced in mice by laser
burns as described previously (19). Briefly, mice were anes-
thetized with intraperitoneal (i.p.) injection of Avertin. Both
pupils were dilated with 1% topical tropicamide; three burns
were delivered (usually at the 9, 12, and 3 o’clock positions
around the optic disc) using a green argon laser (532 nm; 50
mm diameter spot size; 0.05 s duration; 400 mW) and a cover
slide as a contact lens. Fluorescein angiograms were per-
formed 14 days later by taking serial fundus photographs
(Canon) after i.p. injection of 0.3 ml of 1% fluorescein
sodium (Ciba, Summit, N.J.). The percentage of burns devel-
oping late-phase hyperfluorescent spots (evaluated in com-
parison with the retinal normal vasculature) corresponding
to the leakage of fluorescein from newly formed hyperper-
meable vessels was evaluated. Animals were then killed, eyes
were enucleated and either fixed in buffered 3.5% formalin
solution for routine histology or embedded in Tissue TeK
(Miles Laboratories, Naperville, Ill.), and frozen in liquid
nitrogen for cryostat sectioning.
Quantitation of choroidal neovascularization
A quantitative morphometric assessment of thickness of cho-
roidal new vessels was carried out using a computer-assisted
image analysis system (Olympus Micro Image version 3.0 for
Windows 95/NT, Olympus Optical Co. Europe GmBH).
Microscopic images (working magnification of 3200) of
hematoxylin-stained eye section were acquired via a video
camera, digitalized, and analyzed. Frozen serial sections were
cut throughout the entire extent of each burn and the
thickest lesions (at least 5 sections per lesion) was used for the
quantitation studies (96 sections studied). Neovascularization
was estimated by the ratio (B/C) of the thickness from the
bottom of the pigmented choroidal layer to the top of the
neovascular membrane (B) to the thickness of the intact
pigmented choroid adjacent to the lesion (C). The advantage
of this method of quantification (over surface estimation) was
its independence in relation to oblique sections (see example
in Fig. 2c).
Immunofluorescence
Cryostat sections (5 mm in thickness) were fixed first in
acetone at 220°C and then in methanol at 4°C before
incubation with the primary antibodies. Antibodies raised
against mouse PECAM (rat monoclonal antibody; Phar-
Mingen, San Diego, Calif.; diluted 1/20) or mouse type IV
collagen (guinea pig polyclonal antibody produced in our
laboratory; diluted 1/100) were incubated for 1 h at room
temperature. Antibodies to mouse PAI-1 (rabbit polyclonal
antibody produced in our laboratory, 10 mg/ml) were incu-
bated overnight at 4°C. The sections were washed three times
for 10 min in phosphate buffered saline (PBS) before the
appropriate secondary antibodies conjugated to fluorescein-
isothiocyanate (FITC) or Texas red were added. Swine anti-
rabbit (Dakopat, Glostrup, Denmark; diluted 1/40) or rabbit
anti-rat (Sigma, St. Louis, Mo.; diluted 1/40) were applied for
30 min. For double immunofluorescence-labeling studies,
sections were first incubated with the two primary antibodies
and then with FITC- and Texas red-conjugated secondary
antibodies. After three washes in PBS for 10 min each and a
final rinse in 10 mM Tris-HCl buffer, pH 8.8, coverslips were
mounted and labeling was analyzed under an inverted micro-
scope equipped with epifluorescence optics. Staining for
b-galactosidase activity was performed with 5-bromo-4-chloro-
3-indolyl-b-galactopyronoside (X-gal) as described (21). In
some assays, primary anti-PAI-1 antibodies were preabsorbed
for 15 min with recombinant PAI-1 (1 mg/ml, a generous gift
from P. Declerck, Katholieke Universiteit Leuven, Belgium).
Adenovirus-mediated PAI-1 gene transfer
Recombinant adenovirus bearing human PAI-1 (AdCM-
VPAI1), Escherichia coli b-galactosidase (AdCMVlacz) and con-
trol adenovirus (AdRR5) were generated as described (22).
Twenty-four hours after laser spot production, mice were
intravenously (i.v.) injected with 200 ml of control or recom-
binant adenovirus (73108 PFU). After 5 days, blood was
sampled from the right retro-orbital sinus and PAI-1 antigen
was measured by ELISA as reported (22). On day 14, mice
were killed and eyes were excised and processed as described
above. According to regulatory constraints, the virally in-
fected animals were permanently housed under BL3 contain-
ment and, consequently, fluorescein angiograms could not be
performed.
RT-PCR for PAI-1 expression
Total RNA from eyes were extracted using RNeasy Mini Kit
(Qiagen, Chatsworth, Calif.) as described by the manufac-
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turer. PAI-1 mRNA and 28S rRNA were measured in 10 ng
aliquots of total RNA using the GeneAmp Thermostable
rTth reverse transcriptase RNA PCR kit (Perkin Elmer, Nor-
walk, Conn.) and two pairs of primers (Gibco BRL-Life
Technologies, Grand Island, N.Y.): 59-AGGGCTTCATGC-
CCCACTTCTTCA-39 (sense primer) and 59-AGTAGAGGGC-
ATTCACCAGCACCA-39 (antisense primer) for PAI-1 and
59-GTTCACCCACTAATAGGGAACGTGA-39 (sense primer)
and 59-GGATTCTGACTTAGAGGCGTTCAGT-39 (antisense
primer) for 28S. Reverse transcription was performed at 70°C
for 15 min, followed by 2 min incubation at 95°C for
denaturation of RNA–DNA heteroduplexes. Amplification
started by 15 s at 94°C, 20 s at 68°C, and 10 s at 72°C (35 cycles
for PAI-1 and 19 cycles for 28S) and terminated by 2 min at
72°C. RT-PCR products were resolved on 10% acrylamide gels
and analyzed using a Fluor-S MultiImager (Bio-Rad, Hercules,
Calif.) after staining with Gelstar (FMC BioProducts, Rock-
land, Maine) dye. The expected size is 191 bp for PAI-1 and
212 bp for 28S.
Statistical analysis
Data were analyzed with GraphPad Prism 3.0 (San Diego,
Calif.). The x2 test, Student’s t test, one-way ANOVA, and
Newman-Keuls post tests were used to determine whether
there were significant (P,0.01) differences between WT and
PAI-12/2 mice.
RESULTS
Choroidal neovascularization in vivo in PAI-12/2
and WT mice
To determine whether the absence of PAI-1 influences
choroidal neovascularization in vivo, we used a murine
model of retinal photocoagulation with an argon laser.
The photocoagulation induced trauma at the level of
outer retina, retinal pigment epithelium, and Bruch’s
membrane, giving rise to choroidal neovascularization
under the retina similar to that observed in AMD. The
damage of the Bruch’s membrane was immediately
identified by the ophthalmoscopical appearance of a
traumatic retinal bubble at the sites of laser burns.
Fluorescein angiograms performed on day 14 (Fig. 1a,
b) showed the appearance of newly formed microves-
sels with significant leakage of fluorescein in 72%
(32/44) of the laser-induced lesions. The incidence of
leaking spots was reduced to 21% (5/24) in PAI-12/2
mice (Fig. 1c, P,0.001). Histological analysis and im-
munostaining with anti-PECAM and anti-collagen type
IV antibodies confirmed the presence of newly formed
capillaries in lesions identified by fluorescein angiogra-
phy (Fig. 2). WT mice showed typically large ‘mush-
room-like’ areas of choroidal neovascularization at the
site of laser-induced trauma, with migration of retinal
pigmented epithelial cells along newly formed mi-
crovessels (Fig. 2a). The wound was usually not covered
by a continuous layer of retinal pigmented epithelial
cells. In PAI-12/2 mice, the choroidal neovascular
reaction was much more restricted and consisted of
only a diffuse and moderate thickening covered by
confluent retinal pigment epithelium (Fig. 2b). In most
instances, these lesions were only indirectly identified
by examination of the retinal photoreceptor damage.
Immunostaining with anti-type IV collagen or anti-
PECAM antibodies failed to show any significant angio-
genesis above the scarring tissue (Fig. 2d). Neovascular-
ization was estimated by measuring, on serial sections,
the maximal height of the lesion above the choroidal
layer observed in neighboring intact zones. This was
performed by determining the B/C ratio between total
thickness of lesions (‘B’ from the bottom of the choroid
to the top of the neovascular area) to the thickness of
adjacent normal choroid (‘C’). A 45% reduction of the
B/C ratio was observed in PAI-deficient mice
(P,0.001) as compared to WT mice.
PAI-1 is present in the neovascular area
Immunohistochemical staining demonstrated the
presence of PAI-1 exclusively within choroidal neo-
vascular membrane, but not in normal intact zones of
WT mice (Fig. 3a). Controls in which the primary
antibody had been preabsorbed with recombinant
PAI-1 were negative (Fig. 3b). No staining was ob-
served at any location in PAI-12/2 mice (Fig. 3c).
RT-PCR applied on the eyes (Fig. 3d) demonstrated,
14 days after injection with adenoviral vector carrying
AdCMVPAI1, a weak human PAI-1 mRNA expression
in PAI-1-deficient mice.
Figure 1. Fluorescein angiograms carried
out 14 days after laser-induced rupture of
Bruch’s membrane. Fluorescein leakage (ar-
rows) is observed from choroidal new vessels
in WT (a) but not in PAI-12/2 mice showing
only normal vasculature (b). A threefold
reduction in the percentage of leaking spots
was obtained in PAI-12/2 mice (c); n/N 5
number of leaking spots/total number of
laser burns (X 2516.8, P,0.0001).
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PAI-1 adenovirus injection restores choroidal
angiogenesis
To further confirm the role of PAI-1 in choroidal
angiogenesis in vivo, WT and PAI-12/2 mice were
i.v. injected 1 day after laser burns with either a
recombinant adenovirus (AdCMVPAI1) carrying hu-
man PAI-1 cDNA, a control virus (AdRR5), or a
vector carrying LacZ cDNA (AdCMVLacZ). Immuno-
staining with anti-type IV collagen and anti-PECAM
antibodies demonstrated a significant angiogenesis
in PAI-12/2 mice injected with AdCMVPAI1 (Fig. 4a)
but not in PAI-12/2 mice injected with a control
virus (Fig. 4b). The injection of the virus carrying the
LacZ cDNA resulted in the expression of b-galactosi-
dase in the retinal pigmented epithelium (Fig. 4c).
This demonstrates that the recombinant adenovi-
ruses were able to transduce the PAI-1 cDNA into
cells in close proximity to the burn. Four days
after the injection of AdCMVPAI1, the measured
plasma levels of human PAI-1 were higher in
PAI-12/2 mice (mean 7340 ng/ml, range 1850 –
12600) than the normal murine PAI-1 value in WT
mice (2 ng/ml). PAI-1 was undetectable after 2 wk.
Quantitation of the neovascularization on frozen
sections (Fig. 4d ) showed that the human gene
expression in PAI-1-deficient mice resulted in a neo-
vascular thickness ratio (B/C) 90% of that observed
in WT animals. In contrast, neovascularization esti-
mated by the B/C ratio in PAI-1-deficient mice
injected with AdRR5 was similar to that observed in
PAI-1-deficient animals.
Figure 2. Histological analysis after laser
treatment. Heamatoxylin-eosin staining of a
representative large area of choroidal neo-
vascularization at the site of laser-induced
trauma in WT mice (a) and more restricted
reaction in PAI-12/2 mice (b). Immunoflu-
orescence labeling of new vessels in WT (c)
or in PAI-12/2 mice (d) analyzed 14 days
after laser photocoagulation. New vessels
were detected with anti-mouse anti-collagen
type IV antibody (red) and anti-mouse anti-
PECAM antibody (green). R: neural retina;
Ch: choroid defined by yellow arrows which
could contain normal large vessels not in-
volved in the neo angiogenic process; S:
sclera; B: total thickness from the choroid to
the top of the neovascular area; C: thickness
of the choroid-RPE (retinal pigmented epi-
thelium) complex. B/C: ratio of the thick-
ness from the choroid to the top of the
neovascular area, to the thickness of the
choroid-RPE complex measured on this sec-
tion. White arrows localize the laser impact.
Original magnification 2003.
Figure 3. Immunofluorescence labeling and
RT-PCR for PAI-1. 14 days after laser treat-
ment, PAI-1 was detected only in the neovas-
cular area of WT mice (a) and not in PAI-1-
deficient mice (c). Immunostaining
disappeared in WT animals when the pri-
mary antibody was preabsorbed with recom-
binant PAI-1 (1 mg/ml) (b). White arrows
localize the laser burn sites. Original magni-
fication 2003. RT-PCR analysis (d) identify-
ing the PAI-1 mRNA expressed in the eyes of
WT mice (lane 2) and of PAI-1-deficient
mice injected with AdCMVPAI1 (lane 3).
Lane 1 represents molecular weights, lane 4
eyes of PAI2/2 mice and lane 5 negative
control.
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DISCUSSION
Angiogenesis represents an invasive cellular process
requiring the functional activity of a variety of mole-
cules such as growth factors, extracellular matrix pro-
teins, adhesion receptors, and proteolytic enzymes
(23). MMPs and serine proteases have been implicated
in the extracellular matrix remodeling associated with
neo-angiogenesis. Since most MMPs are secreted as
zymogens, their activation requires a limited proteolysis
by plasmin. Neovascularization requires therefore a
delicate balance between the activation of the serine
and metalloproteases and their inhibition by specific
inhibitors. The specific roles of MMPs, plasminogen
activators, and inhibitors in neovascular chorioreti-
nopathies remain largely unexplored.
Previous clinical studies detected measurable con-
centrations of tPA and PAI in the aqueous humor of
normal eyes (24, 25). An increase in Bruch’s mem-
brane TIMP-3 (26) and interphotoreceptor matrix
MMP-2 (27) has been associated with age-related mac-
ular degeneration. In the vitreous fluid of diabetic
patients suffering from proliferative retinopathy, ele-
vated concentrations of ProMMP-9 (28), tPA, and PAI-1
(29) were recently reported to be associated with high
VEGF levels. As PAI-1 and TIMP-3 inhibit MMPs activa-
tion, it might have been anticipated that they reduce
choroidal angiogenesis. The apparent paradox of in-
creased tissue levels of PAI and TIMP-3 in choroidal
pathology associated with neovascularization suggests
that their contribution to the angiogenic ocular disor-
ders could be different from that anticipated. We
reported recently that PAI-1 is a key proangiogenic
molecule during tumorigenesis and that PAI-1 deletion
results in the absence of tumor formation in an animal
model of squamous cells carcinoma (15).
We demonstrate here that PAI-1 plays an important
role in choroidal neovascularization. In a model of
laser-induced choroidal neovascularization, angiogene-
sis detected by fluorescein angiography and neovascu-
lar volume appreciated by immunohistochemistry and
quantitative histology were reduced in PAI-1-deficient
animals. Furthermore, restoration of PAI-1 expression
in these mice by injection with recombinant adenovi-
ruses bearing human PAI-1 cDNA led to a choroidal
neovascularization identical to that observed in WT
animals. It could be argued that the inflammatory
reaction may play a role in the results involving adeno-
viral delivery. This is unlikely, as control and lacZ
viruses were inefficient. Quantification of inflammatory
cells in the lesions failed to demonstrate any significant
difference (data not shown).
Although it has been suggested in a model of reti-
nopathy of prematurity that up-regulation of endoge-
nous PAI-1 could protect from retinal and choroidal
neovascularization (30), in accordance with clinical
observations our results suggest, paradoxically, the op-
posite effect and show that PAI-1 expression is neces-
sary for choroidal angiogenesis.
Taken together with results observed previously in
tumoral models, our observations confirm the role of
PAI-1 in the development of pathological angiogenesis.
The effect of PAI-1 is indeed restricted to tumoral and
ocular pathological neovascularization but is not ob-
served in placentation, embryo-development, and
wound-healing reaction (T. Frandsen, unpublished ob-
servations), which are essentially normal in PAI-1-defi-
cient mice.
Although the exact mechanism of action of PAI-1
remains to be elucidated, at least three different hy-
pothesis can be formulated. PAI-1 could prevent exces-
sive matrix degradation against uPA-mediated degrada-
tion, thereby providing a cell adhesion substrate for
endothelial cell migration. It has been shown in vitro
that excessive proteolysis prevents the coordinated as-
sembly of endothelial cells into capillary shoots (31).
Figure 4. Injection of adenoviral vectors
after laser photocoagulation. In PAI-12/2
mice injected with adenovirus bearing hu-
man PAI-1 cDNA (a), immunostaining of
new vessels showed the same behavior as
that found in WT mice injected with a
control virus (not shown), whereas PAI-
12/2 injected with a control virus failed to
demonstrate significant neovascularization
(b). LacZ expression (in blue) was detected
in the retinal pigment epithelium (arrows)
in mice injected with adenovirus bearing
b-galactosidase cDNA (c). Quantitation of
the neovascularization by the B/C ratio
demonstrated a significant reduction in PAI-
12/2 mice injected with a control virus (t
test, P,0.001) while PAI-12/2 mice injected
with AdCMVPAI1 had a B/C ratio (t test,
P50.06) similar to that calculated in WT
mice (d). n represents the number of differ-
ent lesions analyzed. R: neural retina; Ch:
choroid defined by yellow arrows that could
contain normal large vessels not involved in
the neo-angiogenic process; S: sclera.
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PAI-1 could also be considered as the molecular switch
that governs uPAR- and/or integrin-mediated cell ad-
hesion and release (32). Finally, through the inhibition
of plasmin, uPA, and tPA, PAI-1 could promote angio-
genesis by reducing the angiostatin generation from
plasminogen (33). The use of adenovirus with mutated
PAI-1 forms modulating these different pathways is one
of the strategies that could give new insight into the
mechanisms of PAI-1 action in angiogenesis.
Laser-induced choroidal neovascularization in mice
is useful for basic investigation of choroidal angiogen-
esis, although it probably differs from that occurring
naturally in human AMD. Our observations neverthe-
less emphasize the essential role of PAI-1 in the devel-
opment of subretinal neovascularization and identify
PAI-1 as a potential target for therapeutic retinal anti-
angiogenic strategies.
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